Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

738.75 -50.34 (-6.38%)
Streaming Delayed Price Updated: 2:51 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. 
Via Benzinga
Eli Lilly CEO David Ricks On Q3 Results: The Underlying Growth Story Is Fantastic
Eli Lilly reported its latest quarterly earnings. 
Via Talk Markets
Why Eli Lilly Stock Is Sinking Today
The big pharmaceutical company provided a disappointing Q3 update. 
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Eli Lilly has been a huge winner with its GLP-1 drugs. 
Via The Motley Fool
A Closer Look at Eli Lilly's Options Market Dynamics
Via Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Eli Lilly's stock falls as Q3 earnings miss estimates. 2024 guidance lowered due to IPR&D costs. 
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
The pharma giant blamed "inventory decreases in the wholesaler channel." 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Its products Mounjaro and Zepbound generating over $4 billion in the last quarter. 
Via Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. 
Via The Motley Fool
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's
Eli Lilly's Phase 3b study reveals a 41% reduction in amyloid-related imaging abnormalities in Alzheimer's patients using a modified titration of donanemab. 
Via Benzinga
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing weight loss market. 
Via Benzinga
Will New CFO Offer Annual Guidance For Google Stock?
When Alphabet reports Q3 earnings, Wall Street analysts will look for its new CFO Anat Ashkenazi to set her priorities. 
Via Investor's Business Daily
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach. 
Via The Motley Fool
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
The odds of its new drug getting established in the U.K. are now much lower. 
Via The Motley Fool
Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Elon Musk hinted that Neuralink may develop a brain implant to treat early-stage Alzheimer's, although he noted its limited effectiveness for advanced cases due to extensive neuronal loss. 
Via Benzinga
Eli Lilly's Mirikizumab Shows Long-Term Sustained Efficacy, Safety For Ulcerative Colitis And Crohn's Disease
Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative colitis and Crohn's disease patients. 
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter. 
Via The Motley Fool
2 Soaring Growth Stocks That Are Still Worth Buying
These two companies -- leaders in their industries -- look unstoppable. 
Via The Motley Fool
Tesla To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks. 
Via Benzinga
Gary Black Fights Off Criticism, Says Worst Peformer In Future Fund Was Tesla — Here Are His Holdings That Did Better
Gary Black, Managing Partner of The Future Fund LLC, shared insights on social media platform X regarding his investment performance since January 2022. 
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.